Coronary Revascularization in Patients On Dialysis in China-Retrospective Registry

Summary

Coronary artery disease (CAD) is the leading cause of death in end-stage renal disease (ESRD) patients requiring dialysis. There are limited data on clinical characteristics, treatment strategies and outcomes in this special patient population in China. As a nationwide, observational, multicenter cohort study, this study consecutively included ESRD patients on dialysis with significant CAD at 30 tertiary care centers in 12 provinces in China from January 2015 to June 2021. Patient data collected included demographics, comorbidities, cardiac history, cardiac function, location and severity of CAD, procedural information, medications, and clinical events.

Conditions

• Coronary Artery Disease
• End Stage Renal Disease
• Dialysis

Sponsors & Collaborators

• Aerospace Center Hospital

  collaborator OTHER

• Beijing Chao Yang Hospital

  collaborator OTHER

• Cangzhou Central Hospital of Tianjin Medical University

  collaborator UNKNOWN

• Civil Aviation General Hospital

  collaborator OTHER

• Dongguan Tungwah Hospital

  collaborator OTHER

• Emergency General Hospital

  collaborator OTHER

• Fifth Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• First Central Hospital of Tianjin

  collaborator UNKNOWN

• Fuwai Yunnan Cardiovascular Hospital

  collaborator OTHER

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Henan Provincial Chest Hospital

  collaborator OTHER

• Ningbo No. 1 Hospital

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Peking University Shougang Hospital

  collaborator OTHER

• People's Hospital of Xinjiang Uygur Autonomous Region

  collaborator OTHER

• Tianjin Medical University Second Hospital

  collaborator OTHER

• Shaoxing People's Hospital

  collaborator OTHER

• Shengjing Hospital

  collaborator OTHER

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• the First Affiliated Hospital, Harbin Medical University

  collaborator UNKNOWN

• Zhejiang University

  collaborator OTHER

• People's Hospital of Guangxi Zhuang Autonomous Region

  collaborator OTHER

• The Third People's Hospital of Chengdu

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• Tianjin Union Medicine Center

  collaborator UNKNOWN

• Tongji Hospital

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Xuanwu Hospital, Beijing

  collaborator OTHER

• Wuhan University

  collaborator OTHER

• China-Japan Friendship Hospital

  lead OTHER

Principal Investigators

• Jingang Zheng, MD, PhD · China-Japan Friendship Hospital

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-01-01

Primary Completion

2021-06-30

Completion

2024-06-30

Countries

• China

Study Locations